ArticleFrontiers in oncology2026
Case Report: Adjuvant radiation therapy for cardiac intimal sarcoma with long-term disease control.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac intimal sarcomas (CIS) are rare, aggressive primary cardiac malignancies with limited data guiding adjuvant treatment. We report a case of a 40-year-old woman with bi-atrial CIS who underwent bi-atrial resection and mitral valve replacement, with pathology confirming an MDM2-amplified intimal sarcoma and positive margins (R1). She received four cycles of adjuvant chemotherapy followed by adjuvant radiation therapy (RT) delivered using volumetric modulated arc therapy (VMAT), planned with four-dimensional computed tomography to account for respiratory motion, to a total dose of 60 Gy with a 6-Gy sequential boost. Treatment was well tolerated, with only grade 1-2 acute toxicities that resolved by completion of therapy. At 33 months following completion of RT and 41 months from diagnosis, the patient remains alive and disease-free without evidence of recurrence or significant late toxicity. This case supports the feasibility of incorporating adjuvant RT into a multimodal treatment approach for CIS and suggests that advanced radiation planning techniques may allow safe delivery of curative-intent doses to the heart, although further studies are needed to define its role in this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.